ZA200708458B - Injectable compositions of nanoparticculate immuno-suppressive compounds - Google Patents
Injectable compositions of nanoparticculate immuno-suppressive compoundsInfo
- Publication number
- ZA200708458B ZA200708458B ZA200708458A ZA200708458A ZA200708458B ZA 200708458 B ZA200708458 B ZA 200708458B ZA 200708458 A ZA200708458 A ZA 200708458A ZA 200708458 A ZA200708458 A ZA 200708458A ZA 200708458 B ZA200708458 B ZA 200708458B
- Authority
- ZA
- South Africa
- Prior art keywords
- nanoparticculate
- immuno
- injectable compositions
- suppressive compounds
- suppressive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66269205P | 2005-03-17 | 2005-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200708458B true ZA200708458B (en) | 2009-05-27 |
Family
ID=36954386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200708458A ZA200708458B (en) | 2005-03-17 | 2007-10-03 | Injectable compositions of nanoparticculate immuno-suppressive compounds |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060210638A1 (fr) |
| EP (1) | EP1868576A2 (fr) |
| JP (1) | JP2008533165A (fr) |
| KR (1) | KR20070121758A (fr) |
| CN (1) | CN101175481A (fr) |
| AU (1) | AU2006227623B2 (fr) |
| BR (1) | BRPI0606282A2 (fr) |
| CA (1) | CA2601312A1 (fr) |
| EA (1) | EA200701998A1 (fr) |
| IL (1) | IL185952A0 (fr) |
| MX (1) | MX2007011494A (fr) |
| NO (1) | NO20075295L (fr) |
| WO (1) | WO2006101972A2 (fr) |
| ZA (1) | ZA200708458B (fr) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| PL1663217T3 (pl) | 2003-08-29 | 2010-12-31 | Lifecycle Pharma As | Stałe dyspersje zawierające takrolimus |
| DK1663217T3 (da) * | 2003-08-29 | 2010-11-08 | Lifecycle Pharma As | Faste dispersioner indeholdende tacrolimus |
| MX2007007342A (es) * | 2004-12-15 | 2007-12-11 | Elan Pharma Int Ltd | Formulaciones de tacrolimus nanoparticuladas. |
| PL1909973T3 (pl) | 2005-07-15 | 2019-01-31 | Micell Technologies, Inc. | Polimerowe powłoki zawierające proszek leku o kontrolowanej morfologii |
| WO2007011708A2 (fr) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent a revetement polymere renfermant de la rapamycine amorphe |
| WO2007127363A2 (fr) | 2006-04-26 | 2007-11-08 | Micell Technologies, Inc. | Revêtements contenant plusieurs médicaments |
| BRPI0712130A2 (pt) | 2006-05-30 | 2012-01-17 | Elan Pharma Int Ltd | formulações de posaconazol em nanopartìculas |
| CN101678388B (zh) | 2006-10-23 | 2013-12-11 | 米歇尔技术公司 | 用于在涂覆过程中为基底充电的保持器 |
| US20080138405A1 (en) * | 2006-12-06 | 2008-06-12 | Raheja Praveen | Sirolimus nanodispersion |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| EP2111184B1 (fr) | 2007-01-08 | 2018-07-25 | Micell Technologies, Inc. | Stents comportant des couches biodégradables |
| WO2008127746A1 (fr) | 2007-01-10 | 2008-10-23 | Board Of Regents The University Of Texas System | Administration améliorée de compositions médicamenteuses immunosuppressives par voie pulmonaire |
| KR20090118999A (ko) * | 2007-03-07 | 2009-11-18 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| EP2146707A2 (fr) * | 2007-05-03 | 2010-01-27 | Abraxis BioScience, LLC | Procédés et compositions permettant le traitement de l'hypertension pulmonaire |
| WO2008148013A1 (fr) | 2007-05-25 | 2008-12-04 | Micell Technologies, Inc. | Films de polymères pour le revêtement des dispositifs médicaux |
| ES2634153T3 (es) | 2007-05-30 | 2017-09-26 | Veloxis Pharmaceuticals A/S | Forma de dosificación oral de una vez al día que comprende tacrolimus |
| JP5579057B2 (ja) * | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| US20090130210A1 (en) * | 2007-09-11 | 2009-05-21 | Raheja Praveen | Pharmaceutical compositions of sirolimus |
| US9789233B2 (en) | 2008-04-17 | 2017-10-17 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
| CA2730995C (fr) | 2008-07-17 | 2016-11-22 | Micell Technologies, Inc. | Dispositif medical d'administration de medicament |
| US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
| CN104042612A (zh) | 2008-11-11 | 2014-09-17 | 得克萨斯大学体系董事会 | 哺乳动物雷帕霉素靶蛋白的抑制 |
| US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
| WO2010120552A2 (fr) | 2009-04-01 | 2010-10-21 | Micell Technologies, Inc. | Endoprothèses enduites |
| WO2010121187A2 (fr) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Endoprothèses vasculaires ayant une élution contrôlée |
| CN101897964B (zh) * | 2009-04-27 | 2013-04-10 | 中国农业大学 | 一种预防自身免疫疾病的药物 |
| JP6072539B2 (ja) | 2009-05-27 | 2017-02-01 | アルカーメス ファーマ アイルランド リミテッド | ナノ粒子活性物質組成物におけるフレーク状凝集の軽減 |
| WO2015103447A1 (fr) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Préparations orales de nanoparticules de rapamycine, et utilisation |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| EP2531140B1 (fr) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Endoprothèse et système de pose d'endoprothèse avec une capacité améliorée de pose |
| DK2575769T3 (en) * | 2010-02-17 | 2016-09-26 | Veloxis Pharmaceuticals As | stabilized tacrolismussammensætning |
| US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
| EP2560576B1 (fr) | 2010-04-22 | 2018-07-18 | Micell Technologies, Inc. | Endoprothèses et autres dispositifs ayant un revêtement de matrice extracellulaire |
| EP2593039B1 (fr) * | 2010-07-16 | 2022-11-30 | Micell Technologies, Inc. | Dispositif médical d'administration de médicament |
| CA2834532A1 (fr) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Nanovecteurs synthetiques tolerogenes destines a reduire des reponses impliquant des lymphocytes t cytotoxiques |
| US10464100B2 (en) | 2011-05-31 | 2019-11-05 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
| CA2841360A1 (fr) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Dispositif medical d'administration de medicament |
| US8716363B2 (en) | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| US9492431B2 (en) | 2012-11-08 | 2016-11-15 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
| ES2797376T3 (es) | 2013-01-24 | 2020-12-02 | Palvella Therapeutics Inc | Composiciones para la administración transdérmica de inhibidores de mTOR |
| KR20150123838A (ko) * | 2013-03-04 | 2015-11-04 | 브이티브이 테라퓨틱스 엘엘씨 | 안정한 글루코키나제 활성화제 조성물 |
| EP2967803B1 (fr) | 2013-03-12 | 2023-12-27 | Micell Technologies, Inc. | Implants biomédicaux bioabsorbables |
| US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
| US10357482B2 (en) | 2013-05-03 | 2019-07-23 | Selecta Biosciences, Inc. | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity |
| EP2996629B1 (fr) | 2013-05-15 | 2021-09-22 | Micell Technologies, Inc. | Implants biomedicaux bioabsorbables |
| AU2014269762B2 (en) | 2013-05-22 | 2019-09-12 | Yamaguchi University | Inhibitor for retinochoroidal disorders |
| EP3054948B1 (fr) | 2013-10-08 | 2020-08-12 | AI Therapeutics, Inc. | Rapamycine pour le traitement de la lymphangioléiomyomatose |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| CA2939342A1 (fr) * | 2014-02-11 | 2015-08-20 | Lam Therapeutics, Inc. | Rapamycine destinee au traitement de la lymphangioleiomyomatose |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| WO2015154084A1 (fr) | 2014-04-04 | 2015-10-08 | Lam Therapeutics, Inc. | Préparation à inhaler contenant de la rapamycine pour traiter les pathologies liées à l'âge |
| KR20240123409A (ko) | 2014-09-07 | 2024-08-13 | 셀렉타 바이오사이언시즈, 인크. | 유전자 편집 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물 |
| MX2017004440A (es) | 2014-10-07 | 2017-11-01 | Lam Therapeutics Inc | Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2017019214A1 (fr) | 2015-07-29 | 2017-02-02 | Musc Foundation For Research Development | Formulation de prétraitement d'organe donneur |
| CN105267146B (zh) * | 2015-11-25 | 2018-03-13 | 华北制药集团新药研究开发有限责任公司 | 一种无菌他克莫司纳米混悬滴眼液的制备方法 |
| EP3468554B1 (fr) | 2016-06-08 | 2023-08-09 | Clementia Pharmaceuticals Inc. | Méthodes pour le traitement de l'ossification hétérotopique |
| KR20190100187A (ko) | 2016-11-16 | 2019-08-28 | 클레멘티아 파마슈티컬즈, 인크. | 다중 골연골종(mo)을 치료하는 방법 |
| EP3565520A4 (fr) | 2017-01-06 | 2020-08-19 | Palvella Therapeutics, Inc. | Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation |
| AU2018236123B2 (en) | 2017-03-11 | 2024-04-18 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US20200360268A1 (en) | 2017-08-24 | 2020-11-19 | Jiangsu Hengrui Medicine Co., Ltd. | Injectable pharmaceutical composition containing meloxicam, and preparation method therefor |
| CN108383856B (zh) * | 2018-05-25 | 2020-03-27 | 中国医学科学院生物医学工程研究所 | 他克莫司纳米晶及其人工泪液复合物与制备方法 |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| US20200038560A1 (en) * | 2018-07-31 | 2020-02-06 | Cook Medical Technologies Llc | Limus coatings and methods of use thereof |
| CN112791066B (zh) * | 2019-11-13 | 2024-04-02 | 鲁南制药集团股份有限公司 | 一种注射用西罗莫司缓释微球及其制备方法 |
| CN111450064A (zh) * | 2020-04-09 | 2020-07-28 | 广州中医药大学(广州中医药研究院) | 基于超临界反溶剂法制备西罗莫司包覆颗粒的方法及其制得的西罗莫司包覆颗粒和应用 |
| EP4014963A1 (fr) | 2020-12-16 | 2022-06-22 | Medincell | Composition pharmaceutique |
| US20240226126A1 (en) * | 2021-06-16 | 2024-07-11 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions for treatment of psoriasis |
| GB2612779A (en) | 2021-11-10 | 2023-05-17 | Pharmathen Sa | Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use |
| AU2022351126A1 (en) | 2021-09-27 | 2024-05-09 | Pharmathen S.A. | Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use |
| CN117797093A (zh) * | 2024-02-29 | 2024-04-02 | 中国农业科学院农业环境与可持续发展研究所 | 一种以大环内酯类药物为活性成分的兽用口服纳米液体制剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5194378A (en) * | 1991-01-28 | 1993-03-16 | Merck & Co., Inc. | Process for producing fk-506 |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| PT2198858E (pt) * | 1998-03-26 | 2011-09-01 | Astellas Pharma Inc | Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| EP1642571A3 (fr) * | 2000-12-22 | 2007-06-27 | Baxter International Inc. | Procédé de préparation de particules submicroniques |
| US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| EP1551457A1 (fr) * | 2002-07-16 | 2005-07-13 | Elan Pharma International Limited | Compositions pour doses liquides d'agents actifs nanoparticulaires stables |
| US20040229849A1 (en) * | 2002-09-24 | 2004-11-18 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| DE60322937D1 (de) * | 2002-11-29 | 2008-09-25 | Maria Grazia Roncarolo | Rapamycin und il-10 zur behandlung von autoimmunerkrankungen |
| AU2004240640A1 (en) * | 2003-05-19 | 2004-12-02 | Baxter International Inc. | Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
| DK1663217T3 (da) * | 2003-08-29 | 2010-11-08 | Lifecycle Pharma As | Faste dispersioner indeholdende tacrolimus |
| PL1663217T3 (pl) * | 2003-08-29 | 2010-12-31 | Lifecycle Pharma As | Stałe dyspersje zawierające takrolimus |
| MX2007007342A (es) * | 2004-12-15 | 2007-12-11 | Elan Pharma Int Ltd | Formulaciones de tacrolimus nanoparticuladas. |
-
2006
- 2006-03-16 KR KR1020077023749A patent/KR20070121758A/ko not_active Application Discontinuation
- 2006-03-16 WO PCT/US2006/009510 patent/WO2006101972A2/fr active Application Filing
- 2006-03-16 EP EP06738555A patent/EP1868576A2/fr not_active Withdrawn
- 2006-03-16 CA CA002601312A patent/CA2601312A1/fr not_active Abandoned
- 2006-03-16 AU AU2006227623A patent/AU2006227623B2/en not_active Ceased
- 2006-03-16 BR BRPI0606282-2A patent/BRPI0606282A2/pt not_active IP Right Cessation
- 2006-03-16 CN CNA2006800170788A patent/CN101175481A/zh active Pending
- 2006-03-16 EA EA200701998A patent/EA200701998A1/ru unknown
- 2006-03-16 MX MX2007011494A patent/MX2007011494A/es not_active Application Discontinuation
- 2006-03-16 US US11/376,554 patent/US20060210638A1/en not_active Abandoned
- 2006-03-16 JP JP2008502039A patent/JP2008533165A/ja active Pending
-
2007
- 2007-09-16 IL IL185952A patent/IL185952A0/en unknown
- 2007-10-03 ZA ZA200708458A patent/ZA200708458B/xx unknown
- 2007-10-16 NO NO20075295A patent/NO20075295L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007011494A (es) | 2007-12-06 |
| IL185952A0 (en) | 2008-01-06 |
| BRPI0606282A2 (pt) | 2009-06-09 |
| JP2008533165A (ja) | 2008-08-21 |
| CA2601312A1 (fr) | 2006-09-28 |
| CN101175481A (zh) | 2008-05-07 |
| WO2006101972A2 (fr) | 2006-09-28 |
| EP1868576A2 (fr) | 2007-12-26 |
| WO2006101972A3 (fr) | 2006-12-07 |
| EA200701998A1 (ru) | 2008-02-28 |
| AU2006227623B2 (en) | 2011-10-20 |
| AU2006227623A1 (en) | 2006-09-28 |
| KR20070121758A (ko) | 2007-12-27 |
| NO20075295L (no) | 2007-11-29 |
| US20060210638A1 (en) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200708458B (en) | Injectable compositions of nanoparticculate immuno-suppressive compounds | |
| IL179627A0 (en) | Particulate-stabilized injectable pharmaceutical compositions of posaconasole | |
| GB2426023B (en) | Structured composite compositions for treatment of subterranenan wells | |
| IL184426A0 (en) | Combination of organic compounds | |
| PL2335782T3 (pl) | Zastosowanie kompozycji zawierającej HFCO-1233zd | |
| GB0624290D0 (en) | Novel compositions | |
| AP2008004547A0 (en) | Petsticidal compositions | |
| GB0503337D0 (en) | Compositions | |
| EP1877042A4 (fr) | Compositions ameliorees biologiquement | |
| GB0607085D0 (en) | Novel compositions | |
| IL193359A0 (en) | Ezetimibe compositions | |
| ZA200711068B (en) | Injectable compositions and process for preparation of such compositions | |
| GB0501365D0 (en) | Compositions | |
| EP1991200A4 (fr) | Compositions de fluoroquinolone | |
| GB0502479D0 (en) | Novel compositions | |
| GB0502475D0 (en) | Novel compositions | |
| EP1971327A4 (fr) | Compositions pharmaceutiques d'ilaprazole | |
| GB0504950D0 (en) | Organic compositions | |
| EP1908459A4 (fr) | Composition prévenant le cancer | |
| IL184976A0 (en) | Pharmaceutical compositions containing tricyclic compounds | |
| GB0525321D0 (en) | Novel compositions | |
| IL186606A0 (en) | Compositions and uses of amooranin compounds | |
| GB0412584D0 (en) | Composition of matter | |
| SG10201601998PA (en) | Compositions containing lignan-class compounds | |
| GB0917779D0 (en) | Novel compositions |